Key result
Calcium channel blockers were associated with a marginal increase in overall cancer risk (HR 1.05) compared to other antihypertensives, which disappeared after adjusting for reverse causality.
Why the study?
Whether specific antihypertensive treatments increase cancer risk in patients with hypertension remains controversial.
Do specific antihypertensive treatments increase the risk of cancer in patients with newly diagnosed hypertension?
Cohort (n=270,320)
Do specific antihypertensive treatments increase the risk of cancer in patients with newly diagnosed hypertension?
Hazard Ratio: 1.05 (95% CI 1.01–1.09)
p-value: p=0.017
In a large real-world cohort, first-line antihypertensive medications were not associated with a clinically meaningful increase in overall cancer risk after accounting for reverse causality.
Authors
No takes yet. Share an insight, caveat, or question.
Reassures on cancer safety of antihypertensives; leaves open need for randomized confirmation of specific agents.
Yu et al. (2025) conducted a cohort in Newly diagnosed hypertension (n=270,320). Calcium channel blockers (CCBs) vs. Other antihypertensive treatments was evaluated on Incidence of all types of cancers (HR 1.05, 95% CI 1.01-1.09, p=0.017). Calcium channel blockers were associated with a marginal increase in overall cancer risk (HR 1.05) compared to other antihypertensives, which disappeared after adjusting for reverse causality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: